1h Free Analyst Time
The global cytomegalovirus (cmv) therapeutics market is forecasted to grow by USD 305.6 million during 2025-2030, accelerating at a CAGR of 4.7% during the forecast period. The report on the global cytomegalovirus (cmv) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of immunocompromised populations and transplant procedures, transition toward novel mechanisms of action and improved safety profiles, advancements in diagnostic technologies and prophylactic standards.
The study identifies the rise of adoptive cell therapies and virus-specific t-cells as biological modality as one of the prime reasons driving the global cytomegalovirus (cmv) therapeutics market growth during the next few years. Also, emergence of mrna technology and prophylactic vaccine development and strategic prioritization of oral formulations for long-term outpatient management will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The global cytomegalovirus (cmv) therapeutics market is segmented as below:
By Route Of Administration
- Oral
- Parenteral
- Others
By End-User
- Hospitals
- Specialty clinics
- Transplant centers
By Therapy
- Prophylactic therapy
- Preemptive therapy
- Curative therapy
By Region
- North America
- Europe
- Asia
- Rest of World (RoW)
- Rest of World (RoW)
The report covers the following areas:
- Global cytomegalovirus (cmv) therapeutics market sizing
- Global cytomegalovirus (cmv) therapeutics market forecast
- Global cytomegalovirus (cmv) therapeutics market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Route of Administration
9 Market Segmentation by End-user
10 Market Segmentation by Therapy
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global global cytomegalovirus (cmv) therapeutics market: Astellas Pharma Inc., AstraZeneca Plc, Bausch Lomb Corp., Clinigen Group Plc, Exela Pharma Sciences LLC, F. Hoffmann La Roche Ltd., Fortress Biotech Inc., Fresenius SE and Co. KGaA, Genentech Inc., Gilead Sciences Inc., Jazz Pharmaceuticals Plc, Merck and Co. Inc., Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Thermo Fisher Scientific Inc., UbiVac, VBI Vaccines Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is rise of adoptive cell therapies and virus-specific t-cells as biological modality."
According to the report, one of the major drivers for this market is the increasing prevalence of immunocompromised populations and transplant procedures.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bausch Lomb Corp.
- Clinigen Group PLC
- Exela Pharma Sciences LLC
- F. Hoffmann La Roche Ltd.
- Fortress Biotech Inc.
- Fresenius SE and Co. KGaA
- Genentech Inc.
- Gilead Sciences Inc.
- Jazz Pharmaceuticals PLC
- Merck and Co. Inc.
- Takeda Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd.
- Thermo Fisher Scientific Inc.
- UbiVac
- VBI Vaccines Inc.
